載入中
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
前收盤價
US$6.58
−US$0.02 · -0.30%
盤中時間採用ET。市場資料可能有所延遲。
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
日內區間
目前US$6.58
52週區間
目前US$6.58
盤中時間採用ET。市場資料可能有所延遲。
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
日內區間
目前US$6.58
52週區間
目前US$6.58
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 4.94萬 USD | 5.11萬 USD | 5.74萬 USD | 11.96萬 USD | 2527 USD |
| 毛利 | −4.94萬 USD | −5.11萬 USD | −5.74萬 USD | −11.96萬 USD | −2527 USD |
| 研究與開發 | 204.54萬 USD | 137.18萬 USD | 153.12萬 USD | 441.52萬 USD | 63.54萬 USD |
| 銷售、一般及管理費用 | 357.19萬 USD | 432.2萬 USD | 470.62萬 USD | 446.71萬 USD | 297.53萬 USD |
| 營業費用 | 561.73萬 USD | 569.38萬 USD | 623.74萬 USD | 888.24萬 USD | 361.07萬 USD |
| 利息收入 | 13.29萬 USD | 27.12萬 USD | 5.91萬 USD | — | — |
| 利息支出 | 1.95萬 USD | 3.62萬 USD | — | 2.08萬 USD | — |
| 折舊和攤銷 | 4.94萬 USD | 5.11萬 USD | 5.75萬 USD | 11.3萬 USD | 2514.9 USD |
| 營業利益 | −566.67萬 USD | −574.49萬 USD | −629.48萬 USD | −900.2萬 USD | −361.32萬 USD |
| 淨利 | −385.66萬 USD | −525.47萬 USD | −860.91萬 USD | −992.85萬 USD | −365.6萬 USD |
公司資料更新於 2026年10月12日。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年10月5日 | 1:8 | — | — |
股票分割 | 2026年5月21日 | 1:10 | — | — |
股票分割 | 2025年12月15日 | 1:40 | — | — |
股票分割 | 2023年11月28日 | 1:30 | — | — |
股票分割 | 2022年10月3日 | 1:30 | — | — |
已生效 2026年10月5日
1:8
已生效 2026年5月21日
1:10
已生效 2025年12月15日
1:40
已生效 2023年11月28日
1:30
已生效 2022年10月3日
1:30
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
